Search
50 studies match these filters. Showing 26–50 of 50 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT04889872 | PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 80 sites in total | Recruiting | Not applicable | 2,250target | 80 / 6 | 2021 | Dec 17, 2025 | |
| NCT06455787 | J-Valve Transfemoral Pivotal Study The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team t… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 40 sites in total · contact listed | Recruiting | Not applicable | 194target | 40 / 5 | 2024 | May 4, 2026 | |
| NCT04634240 | Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise re… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 72 sites in total · contact listed | Recruiting | Not applicable | 4,000target | 72 / 2 | 2020 | Jul 24, 2025 | |
| NCT05701358 | Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardia… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 113 sites in total · contact listed | Recruiting | Not applicable | 5,100target | 113 / 17 | 2023 | Jun 19, 2025 | |
| NCT06378632 | AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM Study Design: This is an international, multicenter, observational, non-interventional, prospective, blinded, single-arm, two-period study, to collect patient utterances that will be retrospectively analyzed to determine the sensitivity and UPNR of the HearO system. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 45 sites in total · contact listed | Recruiting | 500target | 45 / 3 | 2022 | Mar 26, 2025 | ||
| NCT05102019 | Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coro… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 96 sites in total | Recruiting | Not applicable | 380target | 96 / 3 | 2022 | Aug 26, 2026 | |
| NCT06297291 | Global Paradise System US Post Approval Study The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 43 sites in total · contact listed | Recruiting | 1,000target | 43 / 1 | 2024 | Aug 12, 2026 | ||
| NCT07069673 | Abbott Cephea Mitral Valve Disease Registry The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding of the impact of cor… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 24 sites in total · contact listed | Recruiting | 1,000target | 24 / 1 | 2025 | Sep 10, 2026 | ||
| NCT05677100 | Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 50 sites in total | Recruiting | Not applicable | 320target | 50 / 2 | 2023 | Aug 25, 2026 | |
| NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empaglifl… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 1,143 sites in total · contact listed | Recruiting | Phase 3 | 11,800target | 1,143 / 51 | 2025 | Sep 16, 2026 | |
| NCT07037459 | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fract… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 657 sites in total | Recruiting | Phase 3 | 5,056target | 657 / 34 | 2025 | Sep 16, 2026 | |
| NCT07610278 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 29 sites in total · contact listed | Recruiting | Phase 2 | 120target | 29 / 1 | 2026 | Jul 30, 2026 | |
| NCT07567001 | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to fi… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 838 sites in total | Recruiting | Phase 3 | 5,610target | 838 / 27 | 2026 | Aug 18, 2026 | |
| NCT05065216 | Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limit… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 86 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 728target | 86 / 10 | 2021 | Sep 14, 2026 | |
| NCT06307652 | Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapag… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 852 sites in total | Recruiting | Phase 3 | 3,850target | 852 / 39 | 2024 | Sep 11, 2026 | |
| NCT06990867 | Optimizing Reperfusion to Improve Outcomes and Neurologic Function The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 83 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 740target | 83 / 18 | 2025 | Mar 13, 2026 | |
| NCT06742723 | A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 771 sites in total | Recruiting | Phase 3 | 5,000target | 771 / 42 | 2025 | Aug 26, 2026 | |
| NCT05485961 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) out… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 557 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 3,110target | 557 / 35 | 2022 | Aug 11, 2026 | |
| NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). Pe… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 557 sites in total · contact listed | Recruiting | Phase 3 | 11,000target | 557 / 20 | 2024 | Sep 17, 2026 | |
| NCT07662213 | A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 209 sites in total | Recruiting | Phase 3 | 1,200target | 209 / 15 | 2026 | Sep 9, 2026 | |
| NCT07213778 | REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 36 sites in total | Recruiting | Phase 3 | 2,000target | 36 / 4 | 2025 | Sep 14, 2026 | |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnos… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 124 sites in total | Recruiting | Phase 3 | 750target | 124 / 15 | 2026 | Aug 14, 2026 | |
| NCT07654361 | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calor… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 71 sites in total · contact listed | Recruiting | Phase 3 | 3,600target | 71 / 1 | 2026 | Aug 10, 2026 | |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell g… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 647 sites in total | Recruiting | Phase 3 | 1,450target | 647 / 2 | 2021 | Aug 19, 2026 | |
| NCT07546929 | HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cel… ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 25 sites in total · contact listed | Recruiting | Phase 2 | 300target | 25 / 1 | 2023 | Apr 23, 2026 |